NDAINTRAVENOUSPOWDER
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
DAPTOMYCIN (daptomycin) by Hikma is 12. First approved in 2023.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibacterial agent administered intravenously that disrupts bacterial cell membrane integrity. It is used to treat serious infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The drug's antimicrobial activity correlates with AUC/MIC ratio, making it effective against resistant bacterial strains.
Peak12.2 years to LOE
Product is at peak commercial stage with established market presence; team size and stability likely well-defined.
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ]. 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain…
Worked on DAPTOMYCIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.